<DOC>
	<DOC>NCT00602680</DOC>
	<brief_summary>The primary objective of the study is to assess the effect of 3 doses of SSR180711C on cognitive performance in patients with mild Alzheimer's Disease (AD). Other objectives are to assess the safety/tolerability of SSR180711C in patients with mild AD.</brief_summary>
	<brief_title>Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Outpatients with diagnosis of mild AD Concomitant or previous treatment by acetylcholinesterase inhibitors and/or memantine Medical condition which may interfere with the study History of epileptic seizures Lens opacity Lack of reliable caregiver The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Alzheimer</keyword>
	<keyword>cognitive</keyword>
</DOC>